SHEPEARD COMMUNITY BLOOD CENTER INCREASES PROTECTION FROM TRANSFUSION-TRANSMITTED INFECTIONS THROUGH USE OF PATHOGEN REDUCTION TECHNOLOGY
INTERCEPT® Blood System reduces the risk of transmitting infectious disease via blood transfusion by inactivating a broad range of viruses, bacteria and protozoa.
AUGUSTA, GA. ( JULY 12, 2016) – Shepeard Community Blood Center is proud to be the FIRST in the State of Georgia to produce pathogen reduced platelet components in which a broad spectrum of pathogens and leukocytes have been inactivated to reduce the risk of transfusion-transmitted infection, including sepsis, and to potentially reduce transfusion-associated graft-versus-host disease. Shepeard supports 21 hospitals in Georgia & South Carolina, and supplies 32,000 components per year.
“Shepeard continuously strives to find ways to utilize the latest innovative technologies to improve the safety and availability of our blood supply,” said Kevin Belanger, Shepeard President/CEO. “The INTERCEPT Blood System provides a proactive approach to address the safety of blood transfusion recipients by helping to protect them from transfusion transmitted infections, including those from certain bacteria and emerging pathogens.”
Click the link below to view the full press release: